{
    "nctId": "NCT00004935",
    "briefTitle": "Herceptin Followed by Chemotherapy in Treating Women With Metastatic Breast Cancer That Overexpresses HER2",
    "officialTitle": "Randomized Phase III Trial of Herceptin\u00ae Followed by Chemotherapy Plus Herceptin\u00ae Versus the Combination of Herceptin\u00ae and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer.",
    "overallStatus": "TERMINATED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 175,
    "primaryOutcomeMeasure": "Time to progression on combined HerChemo (TTPHerChemo)",
    "eligibilityCriteria": "DISEASE CHARACTERISTICS:\n\n* Histologically confirmed HER2-overexpressing metastatic breast carcinoma\n* Clinically or radiologically measurable or evaluable disease\n\n  * Bidimensionally or unidimensionally measurable lesions\n* No ascitic, pleural, or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as only indicator lesion\n* No known clinical brain or meningeal involvement\n* Hormone receptor status:\n\n  * Not specified\n\nPATIENT CHARACTERISTICS:\n\nAge:\n\n* 18 to 70\n\nSex:\n\n* Female\n\nMenopausal status:\n\n* Not specified\n\nPerformance status:\n\n* ECOG 0-1 OR\n* SAKK 0-1\n\nLife expectancy:\n\n* At least 12 weeks\n\nHematopoietic:\n\n* Hemoglobin at least 10 g/dL\n* Platelet count at least 100,000/mm\\^3\n* Absolute neutrophil count at least 2,000/mm\\^3\n\nHepatic:\n\n* Bilirubin normal\n* SGOT and/or SGPT no greater than 2 times upper limit of normal (ULN) (3 times ULN if proven liver metastases) OR\n* No SGOT and/or SGPT greater than 1.5 times ULN if alkaline phosphatase greater than 2.5 times ULN\n\nRenal:\n\n* Creatinine no greater than 1.25 times ULN\n\nCardiovascular:\n\n* LVEF normal\n* No history of atrial ventricular arrhythmia, congestive heart failure, or angina pectoris, even if medically controlled\n* No history of second or third-degree heart blocks\n* No uncontrolled hypertension\n\nOther:\n\n* Not pregnant or nursing\n* Fertile patients must use effective contraception\n* No pre-existing motor or sensory neuropathy grade 2 or greater\n* No psychiatric disorder that would preclude informed consent\n* No other prior malignancy except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix\n* No definite contraindications for use of corticosteroids\n* No other concurrent serious illness or medical condition\n\nPRIOR CONCURRENT THERAPY:\n\nBiologic therapy:\n\n* Not specified\n\nChemotherapy:\n\n* Prior adjuvant or neoadjuvant chemotherapy allowed\n* No more than 2 prior chemotherapy regimens for metastatic disease\n* No prior cumulative dose of doxorubicin greater than 240 mg/m\\^2\n* No prior cumulative dose of epirubicin greater than 360 mg/m\\^2\n* No prior taxanes\n\nEndocrine therapy:\n\n* Prior hormonal therapy as adjuvant treatment or for metastatic disease allowed\n* No concurrent corticosteroids unless started more than 6 months prior to study and at low doses (i.e., no greater than 20 mg methylprednisolone or equivalent)\n\nRadiotherapy:\n\n* Not specified\n\nSurgery:\n\n* Not specified\n\nOther:\n\n* No other concurrent anticancer drugs\n* No other concurrent experimental drugs\n* No concurrent bisphosphonates unless initiated more than 3 months prior to study\n\n  * Chronic use allowed provided bone metastases are not sole indicator lesions",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}